Rapid & Sustained efficacy in PsA and axSpA
0 SAR
Checkout
Overview
Rapid & Sustained efficacy in PsA and axSpAThis Class for
- Physician
- Resident / Fellow
What I will learn?
- Rapid and long-term relief of PsA and axSpA symptoms (joint and skin + ASAS40)
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
Please go to PDF Material for prescribing information
PP-IX-SA-1018
Related Classes
- EULAR 2025: How do risk factors impact progression to Psoriatic Arthritis?
- EULAR 2025 Symposium Highlights
- Effectiveness of Olumiant vs b-tsDMARDs over 2 years.
- The baricitinib experience –a full review of Olumiant in RA
- Prof. Kleyer–BARE BONE –Olumiant and bone strength in RA.
- Exploring improvements in bone strength in RA with Olumiant.
- Real Patient Experience of Taltz in Psoriasis Arthritis
- Clinical Practice in Treating RA - From Expert to You